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EXECUTIVE SUMMARY 
Amoebic gill disease (AGD) is the main disease affecting the Tasmanian salmonid 
industry and the condition has also been described in other major salmon and trout 
producing countries. AGD is caused by Neoparamoeba perurans, and outbreaks of 
the disease appear during the marine grow-out phase, in particular when water 
temperature rises. Some characterisation of the host immune response against the 
parasite has been achieved through gene expression studies and through others 
investigations which focused on antibody responses against N. perurans, particularly 
IgM. A variety of treatments have been tested, but currently the only treatment option 
widely used in Tasmania is freshwater bathing, which represent a high economic 
burden for the industry. Therefore, the development of a vaccine remains a high 
priority for salmon producers and different types of vaccines have been previously 
tested against AGD without success. 
In order to develop a potentially successful vaccine strategy, a better understanding 
of the antibody immune response associated with the disease is necessary. To address 
this general objective, the followings aims were studied in this thesis: 
 Investigate the mucosal and systemic immune response of Atlantic salmon 
against N. perurans, the causative agent of AGD.  
 Investigate mucosal and systemic anti-N. perurans antibody responses to a 
recombinant putative attachment protein of the amoeba, first identified by the 
generation of a cDNA library from the parasite. 
 Investigate vaccine formulations for AGD, using the recombinant protein 
described above. 
 Investigate other mucosal components potentially involved in the host 
response against N. perurans. 
This thesis presents the results obtained from several different experiments aimed at 
addressing the above stated aims. Firstly, an experiment where the immune responses 
of Atlantic salmon were assessed at transcription and antibody production levels, 
after repeated infections with N. perurans. Secondly, an experiment where immune 
responses were assessed after a single infection and fish were fed commercially 
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developed diets containing immunostimulants. We showed that antibody levels do 
not always correlate with mRNA transcription levels identified in AGD gill lesions, 
which is possibly explained by weak correlations existing between protein and 
mRNA abundances in cells and tissues. Additionally, we demonstrated that the use of 
immunostimulants containing diets did not affect the levels of serum or skin mucus 
IgM and were unable to induce IgM and IgT transcription at the site of AGD 
infection. 
Following from this experiment; the systemic and mucosal immune responses of 
Atlantic salmon were studied using two protein-hapten antigens. This study aimed at 
evaluating the best delivery method of antigens to be used in the testing of a vaccine 
candidate in subsequent experiments. The results showed that i.p. injection of 
immunogens emulsified in FCA was the best delivery method for inducing systemic 
and mucosal antibody responses.  
We described the production of a recombinant protein named r22C03, identified as a 
mannose-binding protein-like (MBP-like) similar to attachment factors of other 
amoebae, and a putative attachment factor of N. perurans. This protein was capable 
of inducing systemic and mucosal antibody responses against the amoebae and both 
systemic and mucosal antibodies produced were able to bind the surface of formalin-
fixed N. perurans. The recombinant protein was then tested as a vaccine candidate 
against AGD, following the rationale that by using functional antibodies present in 
mucosal surfaces, the putative attachment factor of N. perurans might be blocked and 
the severity of AGD could potentially be reduced. Fish were immunised with r22C03 
using two different vaccination strategies and then challenged with the parasite. A 
strong antibody response against the recombinant protein was observed in serum and 
mucosal surfaces of vaccinated salmon, but no differences in survival curves or size 
of lesion in the gills were observed. However, a concurrent infection with Yersinia 
ruckeri was present during the experiment, and even though the simultaneous 
presentation of both pathogens could represent a situation more closely related to 
infection patterns observed on commercial farms, survival results obtained after the 
parasite challenge had to be examined with caution in the context of vaccine efficacy 
against N. perurans.  
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Following from the unsuccessful challenge, nanoLC-MS/MS and proteomics 
analyses were used on skin and gill mucus of AGD-affected fish, as a tool to identify 
the changes in the proteome of mucus after repeated infection with amoebae. Proteins 
that have been previously related to gene expression in AGD-affected gills as well as 
proteins that have not been previously described in AGD-affected fish were 
identified and it was proposed that future research should focus on better 
understanding the role these components play in the response against infection with 
N. perurans. 
This thesis provided further understanding into the mucosal responses to AGD. 
However, the role mucosal antibodies play in responses against AGD cannot be 
completely comprehended until the study of IgT responses in AGD-affected fish can 
be completed, as it has been hampered by the lack of available reagents. Finally, 
adjuvants that have been designed specifically to elicit mucosal responses need to be 
fully tested in AGD vaccine formulations. 
